News | September 27, 2011

Health 2.0 Launches CardioEngagement Developer Challenge

September 27, 2011 – Health 2.0 announced the launch of the Novartis CardioEngagement Challenge, asking multi-disciplinary teams of developers to create an interactive solution enabling patients to better manage their cardiovascular health through a customizable, user-friendly interface.

The Novartis challenge is part of a broader, bold new program called the Health 2.0 Developer Challenge; it is designed to spur innovations in the use of technology to improve healthcare outcomes.  The Health 2.0 Developer Challenge is a partnership between Health 2.0 and the Office of the National Coordinator for Health Information Technology (ONC), a division of the Department of Health and Human Services. 

Novartis Pharmaceuticals Corp. is sponsoring the CardioEngagement Challenge to promote innovation in the area of engagement, support and education for patients with cardiovascular disease.

 By taking a more active role in managing their disease, people with cardiovascular disease have the ability to significantly impact half of the risk factors affecting their overall cardiovascular health. Engaging patients is the area both patients and healthcare professionals struggle with most. 

Developers are asked to think big when tackling cardiovascular disease, the number one killer in America. In that spirit, all entrants should consider the following areas:

  • Health support systems through community and family engagement;
  • Improving health education through better patient engagement;
  • Risk profiling tools to promote positive behavior and lifestyle changes
  • Information sharing with appropriate healthcare stakeholders. 


All applications developed for the challenge should leverage existing publicly available data sources (e.g. Healthdata.gov, Health Indicators Warehouse). The competition will favor entries that work across multiple platforms and have the capacity for scalability and easy deployment.

A board of key stakeholders within the healthcare and health technology community will judge entries and select the solution that best addresses the needs of cardiovascular patients everywhere. 

Teams will be asked to submit concepts for their applications in a PowerPoint slide deck and optional video presentation.  Four finalists will be selected among the submissions and will each receive $15,000 to develop a prototype of their concept. The finalists will then present their prototypes in a live demonstration at the United States headquarters of Novartis. 

One winning concept will be selected and the winning team will receive $100,000 to fully develop and launch their concept in the market. 

For more information: www.cardioengagement.org

Related Content

First Patient Enrolled in U.S. Arm of ALIVE Pivotal Heart Failure Trial
News | Heart Failure| October 17, 2017
October 17, 2017 — BioVentrix Inc. recently announced enrollment of the first patient in the U.S.
Medtronic HeartWare HVAD System Approved for Destination Therapy
Technology | Ventricular Assist Devices (VAD)| October 04, 2017
October 4, 2017 — Medtronic received U.S.
Abiomed Receives FDA PMA Approval for Impella RP for Right Heart Failure
Technology | Ventricular Assist Devices (VAD)| September 28, 2017
Abiomed Inc. recently received U.S. Food and Drug Administration (FDA) pre-market approval (PMA) for the Impella RP ...
Boston Scientific Launches Resonate Devices With HeartLogic Heart Failure Diagnostic
Technology | Implantable Cardioverter Defibrillator (ICD)| September 27, 2017
September 27, 2017 — Boston Scientific recently launched the Resonate family of...
BioCardia Announces 12-Month Results from TRIDENT Trial of Stem Cell Delivery System
News | Stem Cell Therapies| September 26, 2017
BioCardia Inc. recently announced 12-month results from the Phase II TRIDENT clinical trial, conducted by the...
CardiAMP Heart Failure Trial Design Presented at Texas Heart Institute Symposium
News | Heart Failure| September 25, 2017
BioCardia Inc. announced the trial design for its pivotal Phase III CardiAMP Heart Failure Trial was presented during...
MyoKardia Presents Additional Positive Data From Phase 2 PIONEER-HCM Study at HFSA 2017
News | Heart Failure| September 21, 2017
MyoKardia Inc. announced that additional positive data from the first patient cohort of its Phase 2 PIONEER-HCM study...
Heart Failure Market to Surpass $16 Billion by 2026
News | Heart Failure| September 19, 2017
The heart failure space across the seven key markets of the U.S., France, Germany, Italy, Spain, the U.K. and Japan is...
Heart Failure Patients, Clinicians Have Differing Perceptions of Risk Level
News | Heart Failure| September 06, 2017
September 6, 2017 — Physicians identified a majority of patients with advanced...
Israeli Hospital Completes First Implant of CORolla Heart Failure Device
News | Heart Failure| September 05, 2017
Rambam Hospital in Haifa, Israel, recently became the first to use the CORolla device from Israeli start-up company...
Overlay Init